Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver

Melanoma Research

Volumn 14, Issue 3, 2004, Pages 217-222

  Agarwala, Sanjiv S ^a   Panikkar, Rajiv ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemoembolization; Intrahepatic chemotherapy; Metastatic melanoma; Ocular melanoma; Phase I trials

Indexed keywords

CISPLATIN; LORAZEPAM; NARCOTIC ANALGESIC AGENT; ONDANSETRON; OPIATE; POLYVINYL ALCOHOL SPONGE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER PAIN; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; EYE CANCER; EYE MELANOMA; FEMALE; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; EYE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; POLYVINYLS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3042793000     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000129377.22141.ea     Document Type: Article

References (24)

1. Egan KM, Sheddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32:239-251.
2. Sahin A, Polans AS, Mehta MP, Auchter RM, Albert DM. Intraocular melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (editors): Cancer: Principles and Practices of Oncology, 6th edition. Philadelphia: Lippincott; 2001, pp. 2070-2090.
3. Scotto J, Fraumeni JF. Melanoma of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 1976; 56:489-491.
4. Wilkes SR, Robertson DM, Kurland LT, Campbell RJ. Incidence of uveal malignant melanoma in the resident population of Rochester and Olmstead County, Minnesota. Am J Ophthalmol 1979; 87:639-641.
5. Woll E, Bedikian A, Lega SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999; 9:575-581.
6. Didolkar MS, Elias EG, Barber NA, Moore RH. Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck. Am J Surg 1980; 140:522-526.
7. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free survival following enucleation for uveal melanoma. Arch Opthalmol 1983; 101:1894-1899.
8. Pack RBS. Pattern of mortality in choroidal malignant melanoma. Br J Ophthalmol 1980; 64:565-575.
9. Kath R, Hayungs J, Bomfeld N, Sauerwein W, Höffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72:2219-2223.
10. Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. Am J Roentgenol 1991; 157:1279-1281.
11. Einhorn LH, Burgess MA, Gottlieb JA. Metastatic patterns of choroidal melanoma. Cancer 1974; 34:1001-1004.
12. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98:383-390.
13. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1983; 52:334-336.
14. Einhorn LH, Burgess MA, Vallejos C, Bodey GP Sr, Gutterman J, Mavligit G, et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 1974; 34:1995-2004.
15. Bedikian AY, Kantarjian HK, Young SE, Bodey GP. Prognosis in metastatic choroidal melanoma. South Med J 1981; 74:574-577.
16. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
17. Agarwala SS, Hauschild A, Glaspy J, Gehlsen KR, Naredi P, O'Day S. Histamine dihydrochloride administered with interleukin-2 increases survival duration in patients with ocular melanoma with liver metastases. Eur J Cancer 2001; 37:S33.
18. Cantore M, Fiorentini G, Aitini E, Davitti B, Cavazzini G, Rabbi C, et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver: report of a phase II study. Tumori 1994; 80:37-39.
19. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589-2595.
20. al-Bassam SH, Munk PL, Sallomi DF, Morris DC, Lee MJ, Chung SW, Connell DG. Chemo-embolization of hepatic tumours. Australas Radiol 1999; 43:165-174.
21. Soulen MC. Chemoembolization of hepatic malignancies. Oncology 1994; 8:77-84.
22. Carrasco CH, Wallace S, Charnsangavej C, Papadopoulos NE, Patt XY, Mavligit GM. Treatment of hepatic metastases in ocular melanoma: embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA 1986; 255:3152-3154.
23. Mavligit GM, Charnsangavej C, Carrasco H, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988; 260:974-976.
24. Sato T, Babazono A, Shields JA, Shields CL, De Potter P, Mastrangelo MJ. Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest 1997; 15:98-105.